» Articles » PMID: 37960353

CCFM1025 Improves Sleep Quality Via Regulating the Activity of the HPA Axis: A Randomized Clinical Trial

Overview
Journal Nutrients
Date 2023 Nov 14
PMID 37960353
Authors
Affiliations
Soon will be listed here.
Abstract

Psychobiotics, a newly identified category of probiotics primarily targeting the gut-brain axis, exhibit tremendous potential in improving sleep quality. In this study, the clinical trial was registered in advance (identifier: NO. ChiCTR2300067806). Forty participants who were diagnosed with stress-induced insomnia were chosen and randomly divided into two groups: one received CCFM1025 at a dose of 5 × 10 CFU ( = 20), while the other was administered a placebo ( = 20), over a period of four weeks. The results revealed that compared to the placebo group (pre: M = 10.10, SD = 2.292; post: M = 8.650, SD = 2.793; pre vs. post: F (1, 38) = 15.41, = 0.4316), the CCFM1025-treated group exhibited a significant decrease in Pittsburgh Sleep Quality Index (PSQI) scores from baseline (pre: M = 11.60, SD = 3.169; post: M = 7.750, SD = 3.697, F (1, 38) = 15.41, = 0.0007). Furthermore, the administration of CCFM1025 was associated with a more pronounced reduction in stress marker concentrations. This effect could potentially be linked to changes in serum metabolites induced by the probiotic treatment, notably daidzein. In conclusion, CCFM1025 demonstrates promise as a psychobiotic strain for enhancing sleep quality.

Citing Articles

Psychobiotics Ameliorate Depression and Anxiety Status in Surgical Oncology Patients: Results from the Study.

Tzikos G, Chamalidou E, Christopoulou D, Apostolopoulou A, Gkarmiri S, Pertsikapa M Nutrients. 2025; 17(5).

PMID: 40077722 PMC: 11901992. DOI: 10.3390/nu17050857.


Can We Modulate Our Second Brain and Its Metabolites to Change Our Mood? A Systematic Review on Efficacy, Mechanisms, and Future Directions of "Psychobiotics".

Garzone S, Charitos I, Mandorino M, Maggiore M, Capozzi L, Cakani B Int J Mol Sci. 2025; 26(5).

PMID: 40076598 PMC: 11899754. DOI: 10.3390/ijms26051972.


The Microbiota-Gut-Brain Axis: Key Mechanisms Driving Glymphopathy and Cerebral Small Vessel Disease.

Che Mohd Nassir C, Che Ramli M, Ghazali M, Jaffer U, Abdul Hamid H, Mehat M Life (Basel). 2025; 15(1).

PMID: 39859943 PMC: 11766513. DOI: 10.3390/life15010003.


Microbiome-Based Therapeutics for Insomnia.

Li C, Chen S, Wang Y, Su Q Int J Mol Sci. 2024; 25(23).

PMID: 39684918 PMC: 11642687. DOI: 10.3390/ijms252313208.


Diet and Disease Development: Mechanisms, Prevention, and Treatment.

Saad S, Chen H Nutrients. 2024; 16(21).

PMID: 39519509 PMC: 11547979. DOI: 10.3390/nu16213676.


References
1.
Rodenbeck A, Hajak G . Neuroendocrine dysregulation in primary insomnia. Rev Neurol (Paris). 2002; 157(11 Pt 2):S57-61. View

2.
Buysse D, Reynolds 3rd C, Monk T, BERMAN S, Kupfer D . The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989; 28(2):193-213. DOI: 10.1016/0165-1781(89)90047-4. View

3.
Yuan M, Breitkopf S, Yang X, Asara J . A positive/negative ion-switching, targeted mass spectrometry-based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue. Nat Protoc. 2012; 7(5):872-81. PMC: 3685491. DOI: 10.1038/nprot.2012.024. View

4.
Pruessner J, Gaab J, Hellhammer D, Lintz D, Schommer N, Kirschbaum C . Increasing correlations between personality traits and cortisol stress responses obtained by data aggregation. Psychoneuroendocrinology. 1998; 22(8):615-25. DOI: 10.1016/s0306-4530(97)00072-3. View

5.
Ko Y, Kim S, Lee S, Jang C . 6,7,4'-Trihydroxyisoflavone, a major metabolite of daidzein, improves learning and memory via the cholinergic system and the p-CREB/BDNF signaling pathway in mice. Eur J Pharmacol. 2018; 826:140-147. DOI: 10.1016/j.ejphar.2018.02.048. View